Genpact G
Genpact scores average on business quality (5.8 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Genpact does
Genpact provides professional services, helping global enterprises manage digital processes and data operations to cut costs. Clients pay ongoing fees for customized workflow solutions.
- What it does best
Genpact converts operational expertise into sticky client relationships, delivering a 22.9% ROE. This high return shows it extracts strong profits from its asset base without heavy capital spending.
- The main risk
Client budget tightening in core professional services can stall contract renewals. Slower enterprise spending directly hits volume expansion and caps revenue acceleration.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin stands at 14.8% alongside a 10.5% ROA. Profitability remains stable as scale efficiencies offset wage inflation.
Genpact builds a switching barrier through deeply embedded enterprise workflows. Its gross margin sits in the middle of the pack at 36.5%, limiting wider competitive separation.
Revenue grew 6.6% to reach $5.2B, showing a steady expansion rate compared to historical periods.
With $1.2B in cash and an interest coverage ratio of 9.8x, debt servicing is manageable. Free cash flow reached $549.0M, showing steady cash generation.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
4 sold $2.3M outside pre-planned sales.
Our sealed record on G
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Genpact scores average on the Cluenex quality check (5.8 of 10), measured against its own industry. Profitability is fair, moat fair, growth slow and financial health fair.
In the last 90 days of SEC Form 4 filings: 4 sold $2.3M outside pre-planned sales.
Nov 5, 2026, after the close.
See G today
- Today's verdict on G, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Genpact (G)”, https://cluenex.com/stocks/g/, data as of Oct 10, 2026.